Brenus Pharma has announced the publication of a scientific article describing its new "off-the-shelf" cancer treatment in "Frontiers in Oncology" Section Cancer Immunity and Immunotherapy. Brenus' ...

Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

Researchers evaluated the immunogenicity of hepatitis A virus vaccination as well as responses in patients with HIV and those on immunosuppressive therapy.

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces further promising data from the fully enrolled Phase 1b/2 study ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...

Vaccinex (VCNX) announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, ...

ViaNautis Bio in Cambridge has signed a strategic collaboration agreement with Eli Lilly and Company to leverage its polyNaut® platform to develop novel products delivering genetic medicines.

A new study demonstrates how AlveoliX’ Lung-on-Chip model offers a more accurate and predictive approach to investigating respiratory diseases and testing potential treatments. AMYRA successfully ...

The new contract will establish new standards that may be used to enhance specificity and sensitivity across industry assay ...

Cardiovascular diseases remain the leading cause of mortality globally, encompassing a range of disorders that affect the heart and blood vessels, including but not limited to ischemic heart disease, ...

Vaxxas, has announced the company has been granted a licence to develop a next-generation vaccine antigen (DS2).